{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T15:37:51Z","timestamp":1789918671101,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["FIS PI17\/01246"],"award-info":[{"award-number":["FIS PI17\/01246"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["PI20\/01621"],"award-info":[{"award-number":["PI20\/01621"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["RD16\/0011\/0028"],"award-info":[{"award-number":["RD16\/0011\/0028"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["SLT002\/16\/0043"],"award-info":[{"award-number":["SLT002\/16\/0043"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019179","name":"Obra Social La Caixa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019179","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jtct.2023.04.008","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T17:55:33Z","timestamp":1682013333000},"page":"473.e1-473.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the Literature"],"prefix":"10.1016","volume":"29","author":[{"given":"Irene","family":"Garc\u00eda-Cadenas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8967-7410","authenticated-orcid":false,"given":"Sara","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Esquirol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Portos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guadalupe","family":"O\u00f1ate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4950-5259","authenticated-orcid":false,"given":"Ana-Carolina","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Miqueleiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Arguello-Tomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Briones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.04.008_bib0001","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.04.008_bib0002","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management","author":"Tefferi","year":"202398801","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2023.04.008_bib0003","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis","volume":"16","author":"Ballen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.008_bib0004","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.008_bib0005","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","article-title":"Management of myelofibrosis after ruxolitinib failure","volume":"99","author":"Harrison","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2023.04.008_bib0006","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/ajh.26349","article-title":"2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: a review of current data and applications on risk stratification and management","volume":"96","author":"Ali","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2023.04.008_bib0007","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.bbmt.2016.02.019","article-title":"Outcome after transplantation according to reduced-intensity conditioning regimen in patients undergoing transplantation for myelofibrosis","volume":"22","author":"Robin","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.008_bib0008","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41409-019-0523-3","article-title":"Pre-hematopoietic cell transplant ruxolitinib in patients with primary and secondary myelofibrosis","volume":"55","author":"Salit","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.008_bib0009","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41375-020-0815-z","article-title":"Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation","volume":"35","author":"Hern\u00e1ndez-Boluda","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.04.008_bib0010","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/bloodadvances.2019001084","article-title":"Survival following allogeneic transplant in patients with myelofibrosis","volume":"4","author":"Gowin","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.04.008_bib0011","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/bmt.2013.173","article-title":"Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib","volume":"49","author":"Jaekel","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.008_bib0012","doi-asserted-by":"crossref","first-page":"873.e1","DOI":"10.1016\/j.jtct.2021.05.016","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis-a systematic review and meta-analysis","volume":"27","author":"Bewersdorf","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.04.008_bib0013","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bbmt.2020.01.010","article-title":"Fludarabine\/busulfan conditioning-based allogeneic hematopoietic cell transplantation for myelofibrosis: role of ruxolitinib in improving survival outcomes","volume":"26","author":"Chhabra","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.008_bib0014","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.008_bib0015","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1182\/blood-2015-10-672071","article-title":"Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation","volume":"127","author":"Mielcarek","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.04.008_bib0016","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3324\/haematol.2016.144139","article-title":"Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide","volume":"102","author":"McCurdy","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2023.04.008_bib0017","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41409-019-0771-2","article-title":"Incorporating posttransplant cyclophosphamide-based prophylaxis as standard-of-care outside the haploidentical setting: challenges and review of the literature","volume":"55","author":"Garc\u00eda-Cadenas","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.008_bib0018","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/s41375-021-01449-1","article-title":"Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study","volume":"36","author":"Kunte","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.04.008_bib0019","doi-asserted-by":"crossref","first-page":"259.e1","DOI":"10.1016\/j.jtct.2022.02.004","article-title":"Post-transplantation cyclophosphamide-based graft- versus-host disease prophylaxis with nonmyeloablative conditioning for blood or marrow transplantation for myelofibrosis","volume":"28","author":"Jain","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.04.008_bib0020","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.bbmt.2020.07.022","article-title":"Survival after allogeneic hematopoietic cell transplantation in myelofibrosis: performance of the Myelofibrosis Transplant Scoring System (MTSS) and development of a new prognostic model","volume":"26","author":"Hern\u00e1ndez-Boluda","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.008_bib0021","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1182\/bloodadvances.2021004846","article-title":"Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era","volume":"5","author":"Yeh","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.04.008_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1057694","article-title":"Controversies and expectations for the prevention of GVHD: a biological and clinical perspective","volume":"13","author":"Watkins","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2023.04.008_bib0023","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/bmt.2016.301","article-title":"Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia","volume":"52","author":"Thakar","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.008_bib0024","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.bbmt.2019.07.010","article-title":"Successful outcome in patients with Fanconi anemia undergoing T cell-replete mismatched related donor hematopoietic cell transplantation using reduced-dose cyclophosphamide post-transplantation","volume":"25","author":"Ayas","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.008_bib0025","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41409-020-01065-0","article-title":"Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation","volume":"56","author":"Sugita","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.008_bib0026","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjh.18483","volume":"200","author":"Zhang","year":"2023","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.04.008_bib0027","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood-2021-146997","article-title":"Phase I\/II study of reduced dosing of post-transplantation cyclophosphamide (PTCy) after HLA-haploidentical bone marrow transplantation","volume":"138","author":"McAdams","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.jtct.2023.04.008_bib0028","article-title":"Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies","author":"Dul\u00e9ry","year":"202358386","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.008_bib0029","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/bmt.2016.225","article-title":"Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease","volume":"52","author":"Garc\u00eda-Cadenas","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.008_bib0030","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bmt.1703846","article-title":"Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning","volume":"31","author":"Valc\u00e1rcel","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.jtct.2023.04.008_bib0031","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.008_bib0032","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.008_bib0033","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41409-020-01092-x","article-title":"Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide as graft-versus-host-disease prophylaxis: impact of HLA donor matching","volume":"56","author":"Garc\u00eda-Cadenas","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.008_bib0034","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.bbmt.2019.06.034","article-title":"Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"McLornan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.008_bib0035","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41409-021-01222-z","article-title":"Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT","volume":"56","author":"Battipaglia","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.008_bib0036","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/j.bbmt.2020.08.029","article-title":"A new standard in graft-versus-host disease prophylaxis? An introduction to Blood and Marrow Transplant Clinical Trials Network 1703","volume":"26","author":"DeFilipp","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.008_bib0037","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00277-019-03673-3","article-title":"Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study","volume":"98","author":"Soltermann","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2023.04.008_bib0038","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1038\/s41409-021-01358-y","article-title":"Low-dose antithymocyte globulin plus low-dose posttransplant cyclophosphamide combined with cyclosporine and mycophenolate mofetil for prevention of graft-versus-host disease after HLA-matched unrelated donor peripheral blood stem cell transplantation","volume":"56","author":"Sun","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.04.008_bib0039","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1182\/blood-2021-153455","article-title":"De-escalation of PTCy dosing in matched allogenic transplants: a single institution retrospective study","volume":"138","author":"Ackula","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.04.008_bib0040","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41598-020-80531-7","article-title":"Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAA","volume":"11","author":"Zu","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtct.2023.04.008_bib0041","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-022-00771-w","article-title":"Low-dose PTCy plus low-dose ATG as GVHD prophylaxis after UD-PBSCT for hematologic malignancies: a prospective, multicenter, randomized controlled trial","volume":"13","author":"Zu","year":"2023","journal-title":"Blood Cancer J"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723012393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723012393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:09:42Z","timestamp":1763003382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723012393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2666636723012393"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.04.008","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the Literature","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}